Population pharmacokinetics of tacrolimus whole blood and peripheral blood mononuclear cell concentrations in stable kidney‐transplanted patients
British Journal of Clinical Pharmacology · 2025-03 · 91 (3) · 761-773
DOI: 10.1111/bcp.16277 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 10.10.2024. Verfasst von Katrine Agergaard und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Regional Health Research, University of Southern Denmark, Esbjerg, Denmark. Hauptthemen laut MEDLINE: Tacrolimus, Leukocytes, Mononuclear, Kidney Transplantation, Immunosuppressive Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: A.P. Møller og Hustru Chastine Mc-Kinney Møllers Fond til almene Formaal, Nyreforeningens Forskningsfond, University Hospital of Southern Denmark.
Abstract (Originalsprache)
Aim
Therapeutic drug monitoring of tacrolimus based on whole blood drug concentrations is routinely performed. The concentration of tacrolimus in peripheral blood mononuclear cells (PMBCs) is likely to better reflect drug exposure at the treatment target site. We aimed to describe the relationship between tacrolimus whole blood and PBMC concentrations, and the influence of patient characteristics on this relationship by developing a population pharmacokinetic model.
Methods
We prospectively enrolled 63 stable adult kidney‐transplanted patients and collected dense (12‐h, n = 18) or sparse (4‐h, n = 45) pharmacokinetic profiles of tacrolimus. PBMCs were isolated from whole blood (Ficoll density gradient centrifugation), and drug concentrations in whole blood and PBMCs were analysed using liquid chromatography‐mass spectrometry. Patient genotype ( CYP3A4/5 , ABCB1, NR1I2 ) was assessed with PCR. Population pharmacokinetic modelling and statistical evaluation was performed using NONMEM.
Results
Tacrolimus whole blood concentrations were well described using a two‐compartment pharmacokinetic model with a lag‐time and first‐order absorption and elimination. Tacrolimus PBMC concentrations were best estimated from whole blood concentrations with the use of a scaling factor, the ratio of whole blood to PBMC concentrations ( R C:PBMC ), which was the extent of tacrolimus distribution into PBMC. CYP3A5*1 non‐expressors and NR1I2‐25 385T allele expressors demonstrated higher R C:PBMC ratios of 42.4% and 60.7%, respectively.
Conclusion
Tacrolimus PBMC concentration could not be accurately predicted from whole blood concentrations and covariates because of significant residual unexplained variability in the distribution of tacrolimus into PBMCs and may need to be measured directly if required for future studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Regional Health Research, University of Southern Denmark, Esbjerg, Denmark.
- Department of Nephrology, Odense University Hospital, Odense, Denmark.
- School of Pharmacy, University of Queensland, Brisbane, Australia.
- Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.
- Department of Nephrology, University Hospital of Southern Denmark, Esbjerg, Denmark.
- Medicinsk Afdeling, Sygehus Lillebælt, Kolding, Denmark.
ORCID-Profile: Katrine Agergaard, Kim Brøsen, Tore Bjerregaard Stage, Maria C Kjellsson
Förderung
- A.P. Møller og Hustru Chastine Mc-Kinney Møllers Fond til almene Formaal
- Nyreforeningens Forskningsfond
- University Hospital of Southern Denmark
- Aase og Ejnar Danielsens Fond
- Region Syddanmark
- Dansk Nefrologisk Selskab
- Odense Universitetshospital
- Syddansk Universitet
Zitieren
APA
Agergaard, K., Thiesson, H. C., Carstens, J., Staatz, C. E., Järvinen, E., Nielsen, F., Christensen, H. D., Juhl-Sandberg, R., Brøsen, K., Stage, T. B., Andersen, D. T., Kjellsson, M. C., & Bergmann, T. K. (2025). Population pharmacokinetics of tacrolimus whole blood and peripheral blood mononuclear cell concentrations in stable kidney‐transplanted patients. British Journal of Clinical Pharmacology, 91(3), 761-773. https://doi.org/10.1111/bcp.16277
Vancouver
Agergaard K, Thiesson HC, Carstens J, Staatz CE, Järvinen E, Nielsen F, et al. Population pharmacokinetics of tacrolimus whole blood and peripheral blood mononuclear cell concentrations in stable kidney‐transplanted patients. British Journal of Clinical Pharmacology. 2025;91(3):761-773. doi:10.1111/bcp.16277
BibTeX
@article{Agergaard2025,
author = {Agergaard, Katrine and Thiesson, Helle C and Carstens, Jan and Staatz, Christine E and Järvinen, Erkka and Nielsen, Flemming and Christensen, Heidi Dahl and Juhl-Sandberg, Rikke and Brøsen, Kim and Stage, Tore Bjerregaard and Andersen, Dorte Terp and Kjellsson, Maria C and Bergmann, Troels K},
title = {Population pharmacokinetics of tacrolimus whole blood and peripheral blood mononuclear cell concentrations in stable kidney‐transplanted patients},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
volume = {91},
number = {3},
pages = {761--773},
doi = {10.1111/bcp.16277}
}
EUVIMED